NASDAQ:LIFE aTyr Pharma (LIFE) Stock Price, News & Analysis → The AI Defense Stock Set to Soar (From Behind the Markets) (Ad) Free LIFE Stock Alerts $1.97 -0.03 (-1.27%) (As of 12:14 PM ET) Add Compare Share Share Today's Range$1.97▼$2.0550-Day Range$1.42▼$2.0252-Week Range$1.08▼$2.70Volume218,195 shsAverage Volume544,900 shsMarket Capitalization$133.79 millionP/E RatioN/ADividend YieldN/APrice Target$23.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get aTyr Pharma alerts: Email Address aTyr Pharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside1,083.3% Upside$23.67 Price TargetShort InterestHealthy0.43% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.97) to ($1.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.96 out of 5 starsMedical Sector622nd out of 939 stocksBiological Products, Except Diagnostic Industry105th out of 157 stocks 3.4 Analyst's Opinion Consensus RatingaTyr Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.67, aTyr Pharma has a forecasted upside of 1,083.3% from its current price of $2.00.Amount of Analyst CoverageaTyr Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.43% of the outstanding shares of aTyr Pharma have been sold short.Short Interest Ratio / Days to CoveraTyr Pharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in aTyr Pharma has recently increased by 167.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldaTyr Pharma does not currently pay a dividend.Dividend GrowthaTyr Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LIFE. Previous Next 3.0 News and Social Media Coverage News SentimentaTyr Pharma has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for aTyr Pharma this week, compared to 1 article on an average week.Search Interest15 people have searched for LIFE on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows6 people have added aTyr Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, aTyr Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.14% of the stock of aTyr Pharma is held by insiders.Percentage Held by Institutions61.72% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for aTyr Pharma are expected to decrease in the coming year, from ($0.97) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of aTyr Pharma is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of aTyr Pharma is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioaTyr Pharma has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.Here's how you can invest >>> About aTyr Pharma Stock (NASDAQ:LIFE)aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.Read More LIFE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LIFE Stock News HeadlinesMarch 26, 2024 | investorplace.com3 Penny Stocks That Could Be Multibaggers in the Making: March EditionMarch 24, 2024 | americanbankingnews.comHead-To-Head Comparison: aTyr Pharma (NASDAQ:LIFE) versus Beam Therapeutics (NASDAQ:BEAM)March 28, 2024 | Behind the Markets (Ad)The AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.March 19, 2024 | americanbankingnews.comaTyr Pharma (NASDAQ:LIFE) Given New $16.00 Price Target at Royal Bank of CanadaMarch 19, 2024 | americanbankingnews.comaTyr Pharma (NASDAQ:LIFE) Stock Rating Reaffirmed by HC WainwrightMarch 18, 2024 | msn.com3 Best Stocks to Buy Now, 3/18/2024, According to Top AnalystsMarch 17, 2024 | finanznachrichten.deaTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdateMarch 16, 2024 | benzinga.comRecap: aTyr Pharma Q4 EarningsMarch 28, 2024 | Behind the Markets (Ad)The AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.March 16, 2024 | finance.yahoo.comaTyr Pharma Full Year 2023 Earnings: Revenues DisappointMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for aTyr Pharma as Lead Candidate efzofitimod Advances in Clinical Trials with Solid Financial FootingMarch 15, 2024 | finance.yahoo.comaTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate ProgressMarch 15, 2024 | finance.yahoo.comQ4 2023 aTyr Pharma Inc Earnings CallMarch 15, 2024 | finance.yahoo.comaTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | investorplace.comLIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023March 14, 2024 | washingtonpost.comAtyr Pharma: Q4 Earnings SnapshotMarch 14, 2024 | globenewswire.comaTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdateMarch 14, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, March 14, 2024March 13, 2024 | benzinga.comaTyr Pharma's Earnings OutlookMarch 13, 2024 | markets.businessinsider.comaTyr Pharma is about to announce earnings — here's what Wall Street expectsFebruary 28, 2024 | globenewswire.comaTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial ResultsFebruary 23, 2024 | finance.yahoo.comWe Think aTyr Pharma (NASDAQ:LIFE) Can Afford To Drive Business GrowthFebruary 21, 2024 | finance.yahoo.comaTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial ParticipantsFebruary 21, 2024 | globenewswire.comaTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial ParticipantsFebruary 15, 2024 | investorplace.comThe 3 Best Penny Stocks to Buy in February 2024February 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), CVS Health (CVS) and Science 37 (SNCE)February 3, 2024 | finance.yahoo.comAfter losing 23% in the past year, aTyr Pharma, Inc. (NASDAQ:LIFE) institutional owners must be relieved by the recent gainSee More Headlines Receive LIFE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2021Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:LIFE CUSIP53217V10 CIK1339970 Webwww.atyrpharma.com Phone(858) 731-8389Fax858-731-8394Employees65Year Founded2005Price Target and Rating Average Stock Price Target$23.67 High Stock Price Target$35.00 Low Stock Price Target$16.00 Potential Upside/Downside+1,083.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,390,000.00 Net MarginsN/A Pretax Margin-14,276.77% Return on Equity-49.84% Return on Assets-39.12% Debt Debt-to-Equity Ratio0.02 Current Ratio6.27 Quick Ratio6.27 Sales & Book Value Annual Sales$350,000.00 Price / Sales387.14 Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book1.30Miscellaneous Outstanding Shares67,750,000Free Float65,623,000Market Cap$135.50 million OptionableOptionable Beta1.25 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Sanjay S. Shukla M.D. (Age 52)M.S., President, CEO & Director Comp: $795.48kMs. Jill M. Broadfoot (Age 62)Chief Financial Officer Comp: $556.62kMs. Nancy E. Denyes Krueger (Age 56)General Counsel & Corporate Secretary Comp: $532.13kXiang-Lei Yang Ph.D.FounderMs. Ashlee DunstonDirector of Investor Relations & Corporate CommunicationsMr. Peter VilligerVice President of Corporate DevelopmentMs. Danielle CampbellVP of Human ResourceDr. Leslie Nangle Ph.D.Vice President of ResearchDr. Ying J. Buechler Ph.D.Executive Director of Biologics Development & ManufacturingDr. David J. King Ph.D. (Age 65)Scientific Consultant Comp: $327.31kMore ExecutivesKey Competitorsbluebird bioNASDAQ:BLUECardiol TherapeuticsNASDAQ:CRDLCellectisNASDAQ:CLLSLENZ TherapeuticsNASDAQ:LENZMolecular PartnersNASDAQ:MOLNView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 84,848 shares on 3/11/2024Ownership: 4.044%Goldman Sachs Group Inc.Bought 143,570 shares on 3/1/2024Ownership: 0.245%Virtu Financial LLCBought 12,747 shares on 2/26/2024Ownership: 0.045%GSA Capital Partners LLPBought 81,605 shares on 2/16/2024Ownership: 0.186%Citadel Advisors LLCSold 3,000 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions LIFE Stock Analysis - Frequently Asked Questions Should I buy or sell aTyr Pharma stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LIFE shares. View LIFE analyst ratings or view top-rated stocks. What is aTyr Pharma's stock price target for 2024? 4 equities research analysts have issued twelve-month price objectives for aTyr Pharma's shares. Their LIFE share price targets range from $16.00 to $35.00. On average, they expect the company's share price to reach $23.67 in the next twelve months. This suggests a possible upside of 1,083.3% from the stock's current price. View analysts price targets for LIFE or view top-rated stocks among Wall Street analysts. How have LIFE shares performed in 2024? aTyr Pharma's stock was trading at $1.41 at the beginning of the year. Since then, LIFE shares have increased by 41.8% and is now trading at $2.00. View the best growth stocks for 2024 here. Are investors shorting aTyr Pharma? aTyr Pharma saw a increase in short interest in March. As of March 15th, there was short interest totaling 289,300 shares, an increase of 167.4% from the February 29th total of 108,200 shares. Based on an average trading volume of 521,200 shares, the days-to-cover ratio is presently 0.6 days. View aTyr Pharma's Short Interest. When is aTyr Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our LIFE earnings forecast. How were aTyr Pharma's earnings last quarter? aTyr Pharma, Inc. (NASDAQ:LIFE) released its earnings results on Monday, August, 9th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.13. When did aTyr Pharma's stock split? aTyr Pharma shares reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO? 3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of aTyr Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX). When did aTyr Pharma IPO? aTyr Pharma (LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers. Who are aTyr Pharma's major shareholders? aTyr Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.04%), Vanguard Group Inc. (4.04%), Stonepine Capital Management LLC (0.82%), Pale Fire Capital SE (0.50%), Goldman Sachs Group Inc. (0.25%) and Goldman Sachs Group Inc. (0.25%). Insiders that own company stock include Jill Marie Broadfoot, John K Clarke, Paul Schimmel and Sanjay Shukla. View institutional ownership trends. How do I buy shares of aTyr Pharma? Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LIFE) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceFed launches fourth dollar overhaulStansberry ResearchThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.